HLA mismatches remain risk factors for acute kidney allograft rejection in patients receiving quadruple immunosuppression with anti-interleukin-2 receptor antibodies

Transplantation

Volumn 85, Issue 3, 2008, Pages 411-416

  Wissing, Karl M ^a   Fomegné, Guy ^a   Broeders, Nilufer ^a   Ghisdal, Lidia ^a   Anh, Dung Hoang ^a   Mikhalski, Dimitri ^a   Donckier, Vincent ^a   Vereerstraeten, Pierre ^a   Abramowicz, Daniel ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

Acute rejection; Anti IL2 receptor antibodies; Dialysis; Human leukocyte antigen; Kidney transplantation

Indexed keywords

ACICLOVIR; BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN A; DACLIZUMAB; GANCICLOVIR; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; STEROID; TACROLIMUS;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; FEMALE; GRAFT SURVIVAL; HLA SYSTEM; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RISK FACTOR; UNSPECIFIED SIDE EFFECT;

ACUTE DISEASE; ANTIBODIES; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-2; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 40049094048     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31816349b5     Document Type: Article

References (37)

1. Webster AC, Woodroffe RC, Taylor RS, et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: Meta-analysis and meta-regression of randomised trial data. BMJ 2005; 331: 810.
2. Meier-Kriesche HU, Steffen BJ, Hochberg AM, et al. Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation 2003; 75: 1341.
3. Adu D, Cockwell P, Ives NJ, et al. Interleukin-2 receptor monoclonal antibodies in renal transplantation: Meta-analysis of randomised trials. BMJ 2003; 326: 789.
4. Patlolla V, Zhong X, Reed GW, Mandelbrot DA. Efficacy of anti-IL-2 receptor antibodies compared to no induction and to antilymphocyte antibodies in renal transplantation. Am J Transplant 2007; 7: 1832.
5. Meier-Kriesche HU, Ojo AO, Hanson JA, et al. Increased impact of acute rejection on chronic allograft failure in recent era. Transplantation 2000; 70: 1098.
6. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378.
7. Vereerstraeten P, Abramowicz D, De Pauw L, Kinnaert P. Absence of deleterious effect on long-term kidney graft survival of rejection episodes with complete functional recovery. Transplantation 1997; 63: 1739.
8. Beckingham IJ, Dennis MJ, Bishop MC, et al. Effect of human leucocyte antigen matching on the incidence of acute rejection in renal transplantation. Br J Surg 1994; 81: 574.
9. McKenna RM, Lee KR, Gough JC, et al. Matching for private or public HLA epitopes reduces acute rejection episodes and improves two-year renal allograft function. Transplantation 1998; 66: 38.
10. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
11. Gillich MS, Heimbach D, Schoeneich G, et al. Comparison of blood group versus HLA-dependent transplantation and its influence on donor kidney survival. Nephrol Dial Transplant 2002; 17: 884.
12. Koene RA. Should the allocation of cadaveric kidneys for transplantation be based on HLA matching? Nephrol Dial Transplant 2002; 17: 717.
13. Su X, Zenios SA, Chakkera H, et al. Diminishing significance of HLA matching in kidney transplantation. Am J Transplant 2004; 4: 1501.
14. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Symphony - Comparing standard immunosuppression to low-dose cyclosporine, tacrolimus or sirolimus in combination with MMF, daclizumab and corticosteroids in renal transplantation. Am J Transplant 2006; 6(suppl 2): 83.
15. Sijpkens YW, Doxiadis II, de Fijter JW, et al. Sharing cross-reactive groups of MHC class I improves long-term graft survival. Kidney Int 1999; 56: 1920.
16. Wissing KM, Abramowicz D, Broeders N, Vereerstraeten P. Hypercholesterolemia is associated with increased kidney graft loss caused by chronic rejection in male patients with previous acute rejection. Transplantation 2000; 70: 464.
17. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605.
18. Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007; 7: 1506.
19. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770.
20. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: Have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004; 4: 1289.
21. Meier-Kriesche HU, Port FK, Ojo AO, et al. Effect of waiting time on renal transplant outcome. Kidney Int 2000; 58: 1311.
22. Goldfarb-Rumyantzev A, Hurdle JF, Scandling J, et al. Duration of end-stage renal disease and kidney transplant outcome. Nephrol Dial Transplant 2005; 20: 167.
23. Mange KC, Joffe MM, Feldman HI. Effect of the use or nonuse of long-term dialysis on the subsequent survival of renal transplants from living donors. N Engl J Med 2001; 344: 726.
24. Halloran PF, Hunsicker LG. Delayed graft function: State of the art. Am J Transplant 2001; 1: 115.
25. Ojo AO, Wolfe RA, Held PJ, et al. Delayed graft function: Risk factors and implications for renal allograft survival. Transplantation 1997; 63: 968.
26. Shoskes DA, Cecka JM. Deleterious effects of delayed graft function in cadaveric renal transplant recipients independent of acute rejection. Transplantation 1998; 66: 1697.
27. Quiroga I, McShane P, Koo DD, et al. Major effects of delayed graft function and cold ischaemia time on renal allograft survival. Nephrol Dial Transplant 2006; 21: 1689.
28. Irish WD, McCollum DA, Tesi RJ, et al. Nomogram for predicting the likelihood of delayed graft function in adult cadaveric renal transplant recipients. J Am Soc Nephrol 2003; 14: 2967.
29. Salahudeen AK, Haider N, May W. Cold ischemia and the reduced long-term survival of cadaveric renal allografts. Kidney Int 2004; 65: 713.
30. Opelz G, Dohler B. Multicenter analysis of kidney preservation. Transplantation 2007; 83: 247.
31. Mange KC, Cherikh WS, Maghirang J, Bloom RD. A comparison of the survival of shipped and locally transplanted cadaveric renal allografts. N Engl J Med 2001; 345: 1237.
32. Roberts JP, Wolfe RA, Bragg-Gresham JL, et al. Effect of changing the priority for HLA matching on the rates and outcomes of kidney transplantation in minority groups. N Engl J Med 2004; 350: 545.
33. Doxiadis II, de Fijter JW, Mallat MJ, et al. Simpler and equitable allocation of kidneys from postmortem donors primarily based on full HLA-DR compatibility. Transplantation 2007; 83: 1207.
34. Vereerstraeten P, Abramowicz D, Andrien M, et al. Allocation of cadaver kidneys according to HLA-DR matching alone would result in optimal graft outcome in most recipients. Transplant Proc 1999; 31: 739.
35. Brennan DC, Daller JA, Lake KD, et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006; 355: 1967.
36. Noel C, Abramowicz D, Durand D, et al. Daclizumab vesus Thymoglobulin in renal transplant recipients with a high immunological risk: A French and Belgian randomized and prospective trial. Am J Transplant 2007; 7: 233.
37. Opelz G, Naujokat C, Daniel V, et al. Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation 2006; 81: 1227.